Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macimorelin - AEterna Zentaris

Drug Profile

Macimorelin - AEterna Zentaris

Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; Ghryvelin; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; Solorel

Latest Information Update: 20 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Consilient Health; Novo Nordisk; University of Queensland
  • Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
  • Mechanism of Action Ghrelin receptor agonists; Ghrelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes - Somatotropin deficiency

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Cachexia
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 13 Jul 2023 Aeterna Zentaris plans to have scientific advice meeting with regulatory authorities to discuss next steps program development
  • 12 Apr 2023 USPTO has issued a Notice of Allowance for Aeterna’s patent application (US 17 375 709) titled, “Use of Macimorelin in Assessing Growth Hormone Deficiency in Children"
  • 12 Apr 2023 AEterna Zentaris intends to temporarily withdraw macimorelin for Somatotropin deficiency (Diagnosis, In adults) in USA from May 2023 until the relaunch with an ulternate commercialization partner (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top